Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascendis Pharma ASASND +0.16%41 3-Year EPS without NRI Growth Rate is 31.40% as of Jun. 2026. GuruFocus rates ASND with a GF Score™ of 41/100. The stock has 3 warning signs investors should review. Among 1,160 Biotechnology companies, Ascendis Pharma AS ranks better than 68.1% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 31.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 14.00% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -11.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Ascendis Pharma AS was 31.40% per year. The lowest was -68.10% per year. And the median was -28.30% per year.
Ascendis Pharma AS (NAS:ASND) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Ascendis Pharma AS 3-Year EPS without NRI Growth Rate Related Terms
ASND vs JAZZ, BBIO, EXEL: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's 3-Year EPS without NRI Growth Rate falls into.
Ascendis Pharma AS 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 31.40% mean?
Ascendis Pharma AS (ASND) has a 3-Year EPS without NRI Growth Rate of 31.40% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ascendis Pharma AS and its competitors. According to the industry distribution chart, Ascendis Pharma AS ranks #370 out of 1160 companies in the Biotechnology industry, placing it in the top 31.9%.
Is Ascendis Pharma AS's 3-Year EPS without NRI Growth Rate too high?
Ascendis Pharma AS's current 3-Year EPS without NRI Growth Rate is 31.40%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.95. Ascendis Pharma AS's value of 31.40% is 96.9% above this industry median. Based on the distribution chart, Ascendis Pharma AS ranks #370 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ascendis Pharma AS has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's 3-Year EPS without NRI Growth Rate compare to JAZZ and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #370 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This puts Ascendis Pharma AS in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.95. Ascendis Pharma AS's value of 31.40% is 96.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascendis Pharma AS's current 3-Year EPS without NRI Growth Rate of 31.40% is 96.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Ascendis Pharma AS and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascendis Pharma AS's current 3-Year EPS without NRI Growth Rate is 31.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current 3-Year EPS without NRI Growth Rate of 31.40%. The current 3-Year EPS without NRI Growth Rate is 31.40% and 96.9% above the Biotechnology industry median of 15.95. Ascendis Pharma AS's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current 3-Year EPS without NRI Growth Rate is 31.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
41GF Score
Get the complete analysis for ASND
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASND has been successfully added to your 
